[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,572,884
  • Shares Outstanding, K 42,447
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 1,335 M
  • EBIT $ 1,436 M
  • EBITDA $ 1,521 M
  • 60-Month Beta 0.58
  • Price/Sales 7.02
  • Price/Cash Flow 15.97
  • Price/Book 3.79

Options Overview Details

View History
  • Implied Volatility 38.49% (-0.56%)
  • Historical Volatility 20.27%
  • IV Percentile 55%
  • IV Rank 14.63%
  • IV High 92.62% on 08/25/25
  • IV Low 29.21% on 12/05/25
  • Expected Move (DTE 36) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.07
  • Today's Volume 484
  • Volume Avg (30-Day) 2,661
  • Put/Call OI Ratio 1.53
  • Today's Open Interest 17,667
  • Open Int (30-Day) 19,142
  • Expected Range 529.05 to 529.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.83
  • Number of Estimates 5
  • High Estimate $7.48
  • Low Estimate $6.07
  • Prior Year $6.41
  • Growth Rate Est. (year over year) +6.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
520.05 +1.73%
on 07/15/26
563.70 -6.15%
on 07/07/26
-19.22 (-3.51%)
since 06/16/26
3-Month
520.05 +1.73%
on 07/15/26
609.35 -13.18%
on 05/06/26
-51.46 (-8.86%)
since 04/16/26
52-Week
272.12 +94.42%
on 07/31/25
609.35 -13.18%
on 05/06/26
+230.89 (+77.44%)
since 07/16/25

Most Recent Stories

More News
BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program

The flights carried manufactured organs, being developed by United Therapeutics The flights are also the first in a series of use cases that will touch at least 26 states...

UTHR : 529.05 (-0.52%)
BETA : 17.64 (-4.80%)
United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR ) announced today it has acquired Thymmune Therapeutics, Inc. ( Thymmune ), a privately held, preclinical stage biotechnology...

UTHR : 529.05 (-0.52%)
United Therapeutics Corporation Announces FDA Approval of the LungFXâ„¢ Device for Centralized Ex Vivo Lung Perfusion

LungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platforms

UTHR : 529.05 (-0.52%)
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks

Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks

UTHR : 529.05 (-0.52%)
These 3 Stocks Lowered Their Share Counts Drastically in Q1

Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively.

PINS : 23.09 (-2.49%)
LUV : 49.43 (+0.37%)
UTHR : 529.05 (-0.52%)
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

VSTS : 16.42 (+5.87%)
CNX : 33.46 (+0.63%)
UTHR : 529.05 (-0.52%)
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

NVMI : 451.13 (-4.52%)
SYF : 74.28 (+0.32%)
UTHR : 529.05 (-0.52%)
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 529.05 (-0.52%)
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis ( IPF ) preserved lung function...

UTHR : 529.05 (-0.52%)
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening...

UTHR : 529.05 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 545.02
2nd Resistance Point 541.25
1st Resistance Point 535.15
Last Price 529.05
1st Support Level 525.27
2nd Support Level 521.50
3rd Support Level 515.40

See More

52-Week High 609.35
Last Price 529.05
Fibonacci 61.8% 480.53
Fibonacci 50% 440.73
Fibonacci 38.2% 400.94
52-Week Low 272.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.